Non-alcoholic Fatty Liver Disease — Efficacy and Safety of Oltipraz in the Patients With Non-alcoholic Fatty Liver Disease
Citation(s)
A Multicenter, Randomized, Double-blind, Placebo-controlled, A Multicenter, Randomized, Double-blind, Placebo-controlled, 3 Parallel Groups, Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Oltipraz in Patients With Non-alcoholic Fatty Liver Disease (Except Liver Cirrhosis)